- Home
- DRMA
as 06-27-2025 4:00pm EST
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.5M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 94.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.57 - $5.00 | Next Earning Date: | 08-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Dermata Therapeutics Inc. News
DRMA Breaking Stock News: Dive into DRMA Ticker-Specific Updates for Smart Investing
ACCESS Newswire
a month ago
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
ACCESS Newswire
2 months ago
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
ACCESS Newswire
3 months ago
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
PR Newswire
3 months ago
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
ACCESS Newswire
3 months ago
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
PR Newswire
4 months ago
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
ACCESS Newswire
4 months ago
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
ACCESS Newswire
5 months ago
Dermata to Present on BioPub on January 31, 2025
Compare DRMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DRMA Dermata Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.